Differential Effects of Ascites and Hepatic Encephalopathy on Waitlist Mortality in Liver Transplantation by MELD 3.0

Overview

Journal Transplant Direct

Publisher Wolters Kluwer

Specialty General Surgery

Date 2024 May 17

PMID 38757050

Authors

Brian T Lee

Nathan T Chen

Tse-Ling Fong

Jennifer L Dodge

Affiliations

Soon will be listed here.

Abstract

Background: MELD 3.0 introduces changes to address waitlist disparities for liver transplant (LT) candidates. Ascites and hepatic encephalopathy (HE) are important milestones in the natural history of cirrhosis regardless of the Model for End-Stage Liver Disease (MELD) score. We aim to assess the impact of ascites and HE and its interaction with MELD 3.0 on waitlist mortality.

Methods: This is a retrospective study of patients listed for LT in the Organ Procurement and Transplantation Network database from 2016 to 2021. The primary outcome was waitlist mortality (death/delisting for too sick to LT). Ascites/HE were classified as moderate ascites without moderate HE (mAscites), moderate HE without moderate ascites (mHE), both moderate ascites/HE (mBoth), and neither. MELD 3.0 scores were categorized as <20, 20-29, 30-39, and ≥40.

Results: Of 39 025 candidates, 29% had mAscites, 3% mHE, and 8% mBoth. One-year waitlist mortality was 30%, 38%, and 47%, respectively, compared with 17% (all < 0.001) for those with neither. In multivariable Cox regression, the adjusted risk of waitlist mortality associated with mAscites (versus neither) was a hazard ratio (HR) of 1.76 (95% confidence interval [CI], 1.55-2.00) when the MELD 3.0 score was <20, significantly higher than when the MELD 3.0 score was 20-29 (HR 1.40; 95% CI, 1.27-1.54), 30-39 (HR 1.19; 95% CI, 1.04-1.35), and ≥40 (HR 1.14; 95% CI, 0.91-1.43, interaction < 0.05 for all). A similar pattern was observed by MELD 3.0 for both moderate ascites/HE.

Conclusions: The presence of moderate ascites alone, or combined with moderate HE, not only increases the risk of waitlist mortality but also has a differential effect by MELD 3.0, especially at lower MELD scores. Earlier strategies addressing this group and improving treatment plans or access to LT regardless of MELD remain needed.

References

Biggins S, Angeli P, Garcia-Tsao G, Gines P, Ling S, Nadim M . Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021; 74(2):1014-1048. DOI: 10.1002/hep.31884. View

Zipprich A, Garcia-Tsao G, Rogowski S, Fleig W, Seufferlein T, Dollinger M . Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int. 2012; 32(9):1407-14. PMC: 3713489. DOI: 10.1111/j.1478-3231.2012.02830.x. View

Somsouk M, Guy J, Biggins S, Vittinghoff E, Kohn M, Inadomi J . Ascites improves upon [corrected] serum sodium plus [corrected] model for end-stage liver disease (MELD) for predicting mortality in patients with advanced liver disease. Aliment Pharmacol Ther. 2009; 30(7):741-8. PMC: 2742706. DOI: 10.1111/j.1365-2036.2009.04096.x. View

Bustamante J, Rimola A, Ventura P, Navasa M, Cirera I, Reggiardo V . Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999; 30(5):890-5. DOI: 10.1016/s0168-8278(99)80144-5. View

Yi Z, Mayorga M, Orman E, Wheeler S, Hayashi P, Barritt Th A . Trends in Characteristics of Patients Listed for Liver Transplantation Will Lead to Higher Rates of Waitlist Removal Due to Clinical Deterioration. Transplantation. 2017; 101(10):2368-2374. PMC: 5667556. DOI: 10.1097/TP.0000000000001851. View

Dolz C, Raurich J, Ibanez J, Obrador A, Marse P, Gaya J . Ascites increases the resting energy expenditure in liver cirrhosis. Gastroenterology. 1991; 100(3):738-44. DOI: 10.1016/0016-5085(91)80019-6. View

Hirode G, Vittinghoff E, Wong R . Increasing Burden of Hepatic Encephalopathy Among Hospitalized Adults: An Analysis of the 2010-2014 National Inpatient Sample. Dig Dis Sci. 2019; 64(6):1448-1457. DOI: 10.1007/s10620-019-05576-9. View

DAmico G, Morabito A, Pagliaro L, Marubini E . Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci. 1986; 31(5):468-75. DOI: 10.1007/BF01320309. View

Shaheen A, Nguyen H, Congly S, Kaplan G, Swain M . Nationwide estimates and risk factors of hospital readmission in patients with cirrhosis in the United States. Liver Int. 2019; 39(5):878-884. DOI: 10.1111/liv.14054. View

10.

Trotter J, Osgood M . MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes. JAMA. 2004; 291(15):1871-4. DOI: 10.1001/jama.291.15.1871. View

11.

Kim W, Biggins S, Kremers W, Wiesner R, Kamath P, Benson J . Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008; 359(10):1018-26. PMC: 4374557. DOI: 10.1056/NEJMoa0801209. View

12.

Fattovich G, GIUSTINA G, Degos F, Tremolada F, Diodati G, Almasio P . Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997; 112(2):463-72. DOI: 10.1053/gast.1997.v112.pm9024300. View

13.

Fichet J, Mercier E, Genee O, Garot D, Legras A, Dequin P . Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy. J Crit Care. 2009; 24(3):364-70. DOI: 10.1016/j.jcrc.2009.01.008. View

14.

Dodge J, Lee B, Kassem A, Biggins S, Rana P, Nadim M . The Conundrum of Patients With Compensated Cirrhosis Requiring Kidney Transplantation; Kidney Alone or Simultaneous Liver Kidney Transplantation. Transplantation. 2022; 107(2):429-437. DOI: 10.1097/TP.0000000000004311. View

15.

Polyak A, Kuo A, Sundaram V . Evolution of liver transplant organ allocation policy: Current limitations and future directions. World J Hepatol. 2021; 13(8):830-839. PMC: 8422916. DOI: 10.4254/wjh.v13.i8.830. View

16.

Hayashi F, Matsumoto Y, Momoki C, Yuikawa M, Okada G, Hamakawa E . Physical inactivity and insufficient dietary intake are associated with the frequency of sarcopenia in patients with compensated viral liver cirrhosis. Hepatol Res. 2013; 43(12):1264-75. DOI: 10.1111/hepr.12085. View

17.

Kim W, Mannalithara A, Heimbach J, Kamath P, Asrani S, Biggins S . MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology. 2021; 161(6):1887-1895.e4. PMC: 8608337. DOI: 10.1053/j.gastro.2021.08.050. View

18.

Balcar L, Tonon M, Semmler G, Calvino V, Hartl L, Incicco S . Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event. JHEP Rep. 2022; 4(8):100513. PMC: 9284386. DOI: 10.1016/j.jhepr.2022.100513. View

19.

Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M . Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology. 2004; 40(3):629-35. DOI: 10.1002/hep.20364. View

20.

Child C, Turcotte J . Surgery and portal hypertension. Major Probl Clin Surg. 1964; 1:1-85. View